Business Information
The group's principal activities are to develop & commercialize first-to-Market biopharmaceuticals to improve the lives of people living with life-threatening diseases or serious medical conditions. It develops enzyme-based therapeutics for the treatment of a variety of diseases and conditions.the products consist of three clinical stage product candidates including two in phase 3 development products: aryplasetm for the treatment of mps vi and neutralasetm for the reversal of anticoagulation by heparin in coronary artery bypass graft surgery. The groups trademarks are Biomarin, Aryplase, Vibrilase, Phenoptin, Neutralase, Phenylase & Neuro Trans. On 2-Jan-03, the group sold certain assets of Glyko Inc. On 18-May-04 the group acquired Ascent Pediatrics.
|
|
Name |
Title
|
Email
|
| Jean-Jacques Bienaime | CEO | N/A | | Christopher Starr | Chief Scientific Officer, Sr. VP | N/A | | Jeffrey Cooper | Sr. VP, CFO | N/A | | Amy Waterhouse | VP - Regulatory, Government Affairs | N/A | | Andrew Ramelmeier | VP - Manufacturing, Process Development | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 84,209 | (28,533) | | 2005 | 25,669 | (74,270) | | 2004 | 18,641 | (187,443)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
